caa a22 4500 445796650 CHVBK 20180317145127.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10620-011-1770-3 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1770-3 Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C [Elektronische Daten] [S. Tohra, S. Taneja, S. Ghosh, B. Sharma, A. Duseja, R. Dhiman, A. Das, Y. Chawla] Background: Sustained virological response (SVR) rates in patients with hepatitis C are heterogeneous and are influenced by a wide range of host and viral factors. Aim: To evaluate the efficacy of combination therapy with pegylated interferon alfa (PEG-IFN-α) and ribavirin (RBV), and document the SVR rates taking into consideration various predictive factors in patients with chronic hepatitis C (CHC) genotype 3. Methods: Ninety-seven treatment-naive patients with CHC genotype 3 (mean age 41.46±11.51years, M:F ratio 79:18), who received a combination of PEG-IFN (α-2a or α-2b) and RBV were retrospectively analyzed (2006-2008) for the early virological response (EVR) at 12weeks, end of treatment response (ETR), and SVR at 6months. Results: Eighty-four (86.6%) patients achieved EVR and 81 (83.5%) achieved ETR, while SVR was achieved in 65 (67.0%) patients. Of the 84 patients who achieved EVR, 77 (91.7%) achieved ETR and 61 (72.6%) achieved SVR at 6months. Age and body mass index (BMI) were found to be important predictors (*P<0.05) of SVR. CHC patients with a history of alcohol intake showed decreased SVR (52%) (*P=0.035) as compared to nonalcoholics (80%). Cirrhotic versus noncirrhotic patients showed no difference in SVR (54.5% vs. 70.7%) (P=0.157). Serum alanine aminotransferase (ALT) (P=0.169) and hepatitis C virus (HCV) RNA levels (P=0.42) also did not have an influence on the SVR. Conclusion: Combination therapy with PEG-IFN-α and RBV demonstrated good tolerability in CHC genotype 3 infection. Age, BMI, and alcohol consumption play an important role in determining treatment outcome. Springer Science+Business Media, LLC, 2011 HCV genotype 3 nationallicence Response to therapy nationallicence Sustained virological response nationallicence Pegylated interferon α+ribavirin nationallicence Tohra S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Taneja S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Ghosh S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Sharma B. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Duseja A. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Dhiman R. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Das A. Department of Histopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Chawla Y. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2449-2455 0163-2116 56:8<2449 2011 56 10620 https://doi.org/10.1007/s10620-011-1770-3 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1770-3 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tohra S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Taneja S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Ghosh S. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Sharma B. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Duseja A. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Dhiman R. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Das A. Department of Histopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 700 1- Chawla Y. Department of Hepatology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/8(2011-08-01), 2449-2455 0163-2116 56:8<2449 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer